[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Octant, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100624330","phase-1-a-phase-12-study-in-healthy-volunteers-and-participants-with-autosomal-dominant-retinitis-pigmentosa-rho-adrp-100624330",false,"NCT07408232","A Phase 1\u002F2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)","A Phase 1\u002F2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of OCT-980 in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa","Phase 1b\u002F2 is active. Inclusion\n\nPhase 1b\u002F2 (Multiple Ascending Dose Escalation in RHO-adRP Patients) Inclusion:\n\n* Participants must have a diagnosis of Rhodopsin-associated, autosomal dominant Retinitis Pigmentosa confirmed by a genetic test that is implemented in accordance with the relevant national requirements\n* Male or female greater than or equal to age 18 (inclusive) at the time of signing the informed consent form\n* Have a body weight \\>50kg, with a body mass index (BMI) from 18.0 to 35.0 kg\u002Fm\\^2 (inclusive) at screening\n* Best Corrected Visual Acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) \\> 55\n* Other than their diagnosis of RHO-adRP, be in good general health, as determined by the Investigator\n* Have sufficient venous access to allow blood sampling for pharmacokinetic analysis and safety laboratory samples\n\nPhase 1b\u002F2 (Multiple Ascending Dose Escalation in RHO-adRP Patients) Exclusion:\n\n* Females who are pregnant or breastfeeding\n* Evidence of any other significant ocular (other than RHO-adRP) and non-ocular disease\u002F disorder\n* Lifetime history of ocular surgery\n* Any prior or current ophthalmologic gene therapy\n* Has a history of major surgery, severe trauma, or bone fracture within 12 weeks before the first dose of the investigational product or planned surgery within 4 weeks after the end of the study","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This integrated Ph1\u002F2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.",[27],"Retinitis Pigmentosa",[29,30,27,31,32,33,34,35,36],"Rhodopsin-associated autosomal dominant Retinitis Pigmentosa","RHO-adRP","Inherited Retinal Disease","autosomal dominant Retinitis Pigmentosa","Retinitis Pigmentosa 4","RP4","RP","Eye Diseases","RECRUITING","2026-09-22",{"date":40,"type":41},"2026-09-24","ACTUAL",{"date":43,"type":41},"2026-03-10",{"date":45,"type":20},"2028-11-01",{"name":47,"class":48},"Octant, Inc.","INDUSTRY",2,""]